TY  - BOOK
TI  - SUBSTANCE AND NON SUBSTANCE RELATED ADDICTION DISORDERS: diagnosis and treatment (1)
SN  - 9781681083438
AV  - RC564 .S837 2017
PY  - 2017///
CY  - [S.l.
PB  - BENTHAM SCIENCE PUBLISHER
KW  - Substance abuse
KW  - Diagnosis
KW  - Treatment
KW  - Compulsive behavior
KW  - Electronic Books
N1  - 2; FOREWORD ; PREFACE ; List of Contributors ; Section I: General Topics ; Neurobiology and Psycho-Social Basis for Addiction and Related Disorders ; KEY LEARNING POINTS; NEUROBIOLOGY OF ADDICTION AND REWARD PATHWAYS; PSYCHOSOCIAL FACTORS; ADVERSE CHILDHOOD EXPERIENCES (ACE); CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Urine Drug Screening (UDS) in the Management of Substance Use Disorders ; KEY LEARNING POINTS; CLINICAL VIGNETTE; DIAGNOSTIC CONSIDERATION; REASONS FOR OBTAINING AN UDS; URINE DRUG SCREENS; Types of Urine Drug Tests; Urine Drug Test as a Follow-up Tool; Urine Sample CollectionChain of Custody; Medication Interfering with UDS; SPECIAL CONSIDERATIONS; Opiate/Opioid Metabolism; Benzodiazepines; Untested Substances; Altered Pharmacokinetic and Pharmacodynamic Parameters; SUMMARY; PATIENT INFORMATION SHEET --; URINE DRUG SCREENS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Genetics of Addiction ; KEY LEARNING POINTS; GENETICS OF ADDICTION; SUMMARY; PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Dual Diagnosis ; KEY LEARNING POINTS; CLINICAL VIGNETTE; BACKGROUND; DIAGNOSTIC CONSIDERATIONS; TREATMENT CONSIDERATIONSTREATMENT OUTCOMES; SUMMARY; DUAL DIAGNOSIS --; PATIENT INFORMATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Pharmacologic Treatment for Psychiatric Disorders Associated with Substance Use Disorders: An Overview ; KEY LEARNING POINTS; INTRODUCTION; Benzodiazepines (Table 1); Antidepressants; Serotonin Syndrome; Syndrome Presentation; Treatment; SSRI Withdrawal Phenomenon; Atypical/Typical Antipsychotics; Dosing; Monitoring; Additional Monitoring Recommended; Other Side Effects; Extrapyramidal Side Effects (EPSE); Treatment of Early --; EPSE; Dystonias and PseudoparkinsonismAkathisia; Treatment of Tardive Dyskinesia; Neuroleptic Malignancy Syndrome (NMS); Mood Stabilizers; Anticonvulsants; Management of Insomnia; SUMMARY; PATIENT INFORMATION --; MEDICATIONS FOR SUBSTANCE USE DISORDERS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Motivational Interviewing ; KEY LEARNING POINTS; BACKGROUND; PROCESS; MOTIVATION ENHANCEMENT; THE STAGES OF CHANGE; SUMMARY; MOTIVATIONAL INTERVIEW-PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Section II: Substance-Related Addiction Disorders (Alphabetical); Alcohol Use Disorders KEY POINTS; CLINICAL VIGNETTE; INTRODUCTION; Epidemiology; Etiology; Diagnosis; Non-Pharmacologic Interventions; Pathophysiology of Alcohol Use Disorders (AUD); PHARMACOTHERAPY FOR ALCOHOL USE DISORDERS (AUD); Management of Outpatient Alcohol Withdrawal; FDA Approved Medications for Alcohol Use Disorder 26.; Disulfiram (Antabuse) 19, 21, 27.; Naltrexone (Revia (PO), Vivitrol (IM)); Acamprosate (Campral) 21, 28, 30.; Combination Therapy; Non-FDA Approved Pharmacotherapies for AD; SUMMARY; CLINICAL VIGNETTE RESOLUTION; PROVIDER RESOURCES; 2; b
UR  - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1483672&site=eds-live&custid=s3260518
ER  -